Every Friday, The Leadership Edit follows people taking new roles across European biotech and what their moves may tell us about the companies they join. This week: an immediate CEO change at Pharming, a scientific leadership vacancy at Evotec and a new finance chief at Nanobiotix.
Designing biologics for commercial success
slider, Sponsored PublicationsJustyna Adamczyk, Associate VP Integrated MS&T at Rezon Bio, discusses why integrating development and manufacturing strategies is key to improving late-stage efficiency and commercialization readiness.
The Bridge to your success
slider, Sponsored PublicationsCustomized Enzymes and Reagents from New England Biolabs. Creating the right partnership is essential when pioneering a new life science product.
Novartis bets up to $7.8B on Abogen’s mRNA autoimmune therapy
Latest NewsNovartis is paying China’s Abogen Biosciences $575 million (€512 million) upfront for global rights to ABO2203, an experimental treatment that uses mRNA to make a B-cell-depleting drug inside the patient’s body.
Pharming changes CEO, Evotec loses CSO and Nanobiotix hires CFO
Latest NewsEvery Friday, The Leadership Edit follows people taking new roles across European biotech and what their moves may tell us about the companies they join. This week: an immediate CEO change at Pharming, a scientific leadership vacancy at Evotec and a new finance chief at Nanobiotix.
Amplio’s Phase 1b data hint at better first-line arthritis treatment
Latest NewsAmsterdam-based Amplio Pharma has reported early clinical evidence that its experimental treatment NovoBioJect boosts the active form of methotrexate inside immune cells. The company is seeking about €10 million to test whether the approach improves disease control in rheumatoid arthritis.
GSK adds liver candidate from Wave RNA partnership
Latest NewsGSK has selected a liver disease drug candidate from its collaboration with Wave Life Sciences for further development, triggering a $12 million (€11 million) milestone payment to the U.S.-based biotech.
Highlight Therapeutics’ skin cancer injections show promise in Phase 2b
Latest NewsSpain’s Highlight Therapeutics reported that its lead candidate, BO-112, met its Phase 2b endpoint in localized basal cell carcinoma, with 61% of evaluable patients achieving a response.
Europe’s CGT advantage at risk
slider, Sponsored PublicationsIndustry leaders at Advanced Therapies Europe 2026 warned that Europe must tackle barriers across commercialisation, regulation, reimbursement, manufacturing and patient access to retain its global leadership.
Boehringer, Zealand obesity drug face tolerability questions after Phase 3 success
Latest NewsBoehringer Ingelheim’s survodutide delivered average weight loss of up to 13.1% in a Phase 3 trial involving people with overweight or obesity and type 2 diabetes, but gastrointestinal side effects caused 18% of patients receiving the drug to stop treatment.
Sanofi pays $1B upfront to expand Regeneron alliance beyond Dupixent
Latest NewsSanofi will pay Regeneron Pharmaceuticals $1 billion upfront (€0.9 billion) to expand the alliance that led to the blockbuster Dupixent with four antibody candidates designed to work longer between doses.